[go: up one dir, main page]

AR129311A1 - Composiciones y métodos para inhibir la expresión de mapt - Google Patents

Composiciones y métodos para inhibir la expresión de mapt

Info

Publication number
AR129311A1
AR129311A1 ARP230101180A ARP230101180A AR129311A1 AR 129311 A1 AR129311 A1 AR 129311A1 AR P230101180 A ARP230101180 A AR P230101180A AR P230101180 A ARP230101180 A AR P230101180A AR 129311 A1 AR129311 A1 AR 129311A1
Authority
AR
Argentina
Prior art keywords
gene expression
mapt
pharmaceutical composition
reducing
rnai oligonucleotide
Prior art date
Application number
ARP230101180A
Other languages
English (en)
Inventor
Bob Dale Brown
Henryk T Dudek
Seongmoon Cheong
Shiyu Wang
Travis Grim
Matthew Guese Costales
Maire Jung
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of AR129311A1 publication Critical patent/AR129311A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan oligonucleótidos que inhiben la expresión génica MAPT, incluidos los oligonucleótidos conjugados con un ligando de direccionamiento (por ejemplo, un resto lipídico). También se proporcionan composiciones que incluyen los mismos y usos de los mismos, particularmente usos relacionados con el tratamiento de enfermedades, trastornos y/o condiciones asociadas con la expresión génica MAPT. Reivindicación 1: Un oligonucleótido de ARNi para reducir la expresión génica de MAPT, comprendiendo el oligonucleótido una cadena de sentido y una cadena antisentido, en donde la cadena de sentido y la cadena antisentido forman una región dúplex, en donde la cadena antisentido comprende una región de complementariedad con una secuencia diana de ARNm de MAPT de cualquiera de SEQ ID Nº 912 - 1295, y en donde la región de complementariedad tiene una longitud de al menos 15 nucleótidos contiguos. Reivindicación 101: Una composición farmacéutica que comprende el oligonucleótido de ARNi de cualquiera de las reivindicaciones 1 a 100, y un portador, agente de administración o excipiente farmacéuticamente aceptable. Reivindicación 104: Un método para reducir la expresión génica de MAPT en una célula, una población de células o un sujeto, comprendiendo el método el paso de: i. poner en contacto la célula o la población de células con el oligonucleótido de ARNi de cualquiera de las reivindicaciones 1 a 100, o la composición farmacéutica de la reivindicación 101; o ii. administrarle al sujeto el oligonucleótido de ARNi de cualquiera de las reivindicaciones 1 a 100, o la composición farmacéutica de la reivindicación 101. Reivindicación 105: El método de la reivindicación 104, en donde reducir la expresión génica de MAPT comprende reducir una cantidad o nivel de ARNm de MAPT, una cantidad o nivel de proteína Tau, o ambos. Reivindicación 113: El método de cualquiera de las reivindicaciones 102 - 112, en donde el oligonucleótido de ARNi o la composición farmacéutica se administra en combinación con una segunda composición o agente terapéutico.
ARP230101180A 2022-05-12 2023-05-12 Composiciones y métodos para inhibir la expresión de mapt AR129311A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263364609P 2022-05-12 2022-05-12

Publications (1)

Publication Number Publication Date
AR129311A1 true AR129311A1 (es) 2024-08-14

Family

ID=86710745

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101180A AR129311A1 (es) 2022-05-12 2023-05-12 Composiciones y métodos para inhibir la expresión de mapt

Country Status (11)

Country Link
US (1) US20230416742A1 (es)
EP (1) EP4522747A1 (es)
KR (1) KR20250011918A (es)
CN (1) CN119173631A (es)
AR (1) AR129311A1 (es)
AU (1) AU2023269281A1 (es)
CO (1) CO2024015311A2 (es)
DO (1) DOP2024000225A (es)
IL (1) IL316934A (es)
TW (1) TW202400792A (es)
WO (1) WO2023220349A1 (es)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
DE69431669T2 (de) 1993-09-02 2003-10-23 Ribozyme Pharmaceuticals, Inc. Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
DK1309726T4 (en) 2000-03-30 2019-01-28 Whitehead Inst Biomedical Res RNA Sequence-Specific Mediators of RNA Interference
KR100872437B1 (ko) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
AU2002347981A1 (en) 2001-11-07 2003-05-19 Applera Corporation Universal nucleotides for nucleic acid analysis
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US20090018097A1 (en) 2005-09-02 2009-01-15 Mdrna, Inc Modification of double-stranded ribonucleic acid molecules
GB0605337D0 (en) * 2006-03-17 2006-04-26 Genomica Sau Treatment of CNS conditions
JP5721426B2 (ja) * 2007-04-05 2015-05-20 ザ ジェイ．ディヴィッド グラッドストン インスティテューツ 神経の過度な興奮を緩和する薬剤を識別する方法
PT2341943T (pt) 2008-09-22 2019-02-06 Dicerna Pharmaceuticals Inc Composições e métodos para a inibição específica de expressão génica por dsrna que possui modificações
EP2379083B1 (en) 2008-12-18 2017-08-16 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
RU2014119787A (ru) 2011-10-25 2015-12-10 Айсис Фармасьютикалс, Инк. Антисмысловая регуляция экспрессии gccr
EP3569711B1 (en) 2014-12-15 2021-02-03 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
US10513701B2 (en) * 2015-03-25 2019-12-24 Università Degli Studi Di Trento RNA interference mediated therapy for neurodegenerative diseases
MX2019002339A (es) 2016-09-02 2019-05-16 Dicerna Pharmaceuticals Inc Analogos de 4'-fosfato y oligonucleotidos que los comprenden.
KR20230004448A (ko) * 2020-03-18 2023-01-06 유니버시티 오브 매사추세츠 Mapt 조절을 위한 올리고뉴클레오티드
MX2023001450A (es) * 2020-08-04 2023-04-14 Dicerna Pharmaceuticals Inc Composiciones y metodos para la inhibicion de la expresion de plp1.

Also Published As

Publication number Publication date
CO2024015311A2 (es) 2024-12-30
IL316934A (en) 2025-01-01
AU2023269281A1 (en) 2024-10-10
WO2023220349A1 (en) 2023-11-16
TW202400792A (zh) 2024-01-01
KR20250011918A (ko) 2025-01-22
CN119173631A (zh) 2024-12-20
EP4522747A1 (en) 2025-03-19
DOP2024000225A (es) 2024-12-15
US20230416742A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
KR102737464B1 (ko) 안지오포이에틴-유사 3 (ANGPTL3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물, 및 사용 방법
CN111107853B (zh) 用于抑制载脂蛋白C-III (APOC3)的表达的RNAi试剂和组合物
JP7488254B2 (ja) １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法
TWI386225B (zh) 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
US8686128B2 (en) Agent for targeting c-Jun mRNA
ES2537568T3 (es) Nuevos fármacos para inhibición de la expresión genética
JP6944942B2 (ja) ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
EA035433B1 (ru) Модуляторы фактора в комплемента
JP2012193210A (ja) 眼の障害の治療のためのＲｈｏキナーゼのＲＮＡｉ媒介抑制
KR20080091108A (ko) 안구의 혈관신생 치료용 ＨＩＦ１Ａ의 ＲＮＡⅰ－매개 억제
NZ716816A (en) Modulation of prekallikrein (pkk) expression
JPWO2017068790A1 (ja) 核酸複合体
WO2023051822A1 (zh) 用于治疗与pcsk9相关疾病的靶向寡核苷酸
CN116322707A (zh) 用于调节scn2a的化合物和方法
RU2663100C2 (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
US20240335556A1 (en) Compounds and Methods for Reducing DMPK Expression
AR129311A1 (es) Composiciones y métodos para inhibir la expresión de mapt
TW202140788A (zh) 用於調節ｓｃｎ１ａ表現之化合物及方法
JP2024071571A (ja) ミトコンドリアアミドキシム還元成分１（ｍａｒｃ１）発現を阻害するための組成物および方法
CN114555188A (zh) 治疗apoc3相关疾病和病症的方法
CN113728104A (zh) 用于调节ube3a-ats的化合物和方法
JP7394815B2 (ja) ＮＲＡＲＰ遺伝子の発現を阻害するためのｓｉＲＮＡ、並びにそのための方法及び組成物におけるそれらの使用
US10260067B2 (en) Enhancing dermal wound healing by downregulating microRNA-26a
US20040162249A1 (en) Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotides inhibition of human replication-initiation proteins
US8318922B2 (en) Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins